source
- Travere pays Everest $112M upfront to grow rare kidney disease pipelineTravere Therapeutics is enlisting the help of China-based Everest Medicines to bolster its rare kidney disease pipeline beyond its approved medicine Filspari. The San Diego biotech is doling out $1…Endpoints · 2mo ago↗ source
- Legend Biotech shares first in vivo CAR-T data, its next act after CarvyktiLegend Biotech’s long-awaited first showing of in vivo CAR-T data is here, fueling momentum in the growing field. Legend reported results Tuesday on 12 lymphoma patients from an investigator-initia…Endpoints · 2mo ago↗ source
- AbiVax falls as safety worries cloud ‘landmark’ immune drug resultsA handful of cancer cases reported among treatment recipients overshadowed efficacy results analysts described as “best-in-disease” and sent shares down more than 30%.